Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 3, Pages 458
Publisher
MDPI AG
Online
2021-01-26
DOI
10.3390/cancers13030458
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane
- (2020) Nazli Bahrami et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer
- (2020) James R Whittle et al. CLINICAL CANCER RESEARCH
- Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2− Breast Cancer: A Prospective Phase II Study
- (2020) Naoki Hayashi et al. Clinical Breast Cancer
- PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
- (2020) Marzia Del Re et al. PHARMACOLOGICAL RESEARCH
- Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer
- (2020) Jinming Li et al. JAMA Network Open
- Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
- (2019) Fausto Petrelli et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
- (2019) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States
- (2019) Ashley C. Pariser et al. BREAST CANCER RESEARCH AND TREATMENT
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Cristina Saura et al. LANCET ONCOLOGY
- Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
- (2019) Li-Tong Yao et al. World Journal of Clinical Cases
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
- (2019) Sara A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
- (2019) Aleix Prat et al. LANCET ONCOLOGY
- FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
- (2018) Anand Shah et al. CLINICAL CANCER RESEARCH
- BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose
- (2018) Federico Lucantoni et al. Oncotarget
- Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells
- (2018) Pradip De et al. Scientific Reports
- Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
- (2018) P Cottu et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
- (2018) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials
- (2017) Lei Huang et al. Expert Review of Anticancer Therapy
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
- (2016) G. Curigliano et al. BREAST
- Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
- (2016) Florence Lerebours et al. CANCER
- FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2016) A. J. Walker et al. CLINICAL CANCER RESEARCH
- Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer
- (2016) Jianfeng Lu et al. MOLECULAR CANCER THERAPEUTICS
- The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
- (2016) Jiandong Chen Cold Spring Harbor Perspectives in Medicine
- Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
- (2016) Laura M. Spring et al. JAMA Oncology
- Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
- (2015) D Merino et al. ONCOGENE
- Optimum duration of neoadjuvant letrozole to permit breast conserving surgery
- (2014) Robert Carpenter et al. BREAST CANCER RESEARCH AND TREATMENT
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
- (2013) Takashi Hojo et al. BREAST
- St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
- (2013) Nadia Harbeck et al. Breast Care
- The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
- (2013) Matthew J. Ellis et al. Cancer Discovery
- Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
- (2012) E. Alba et al. ANNALS OF ONCOLOGY
- Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
- (2012) Irene Kuter et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
- (2012) Antonio Llombart-Cussac et al. Clinical & Translational Oncology
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondria and cell death: outer membrane permeabilization and beyond
- (2010) Stephen W. G. Tait et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain
- (2008) E. Christine Pietsch et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Transcriptional control of human p53-regulated genes
- (2008) Todd Riley et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now